Literature DB >> 25635976

Treatment of different-aged children under bispectral index monitoring with intravenous anesthesia with propofol and remifentanil.

J-M Zhang1, F Wang, Z Xin, T-T Zi, H Lv.   

Abstract

OBJECTIVE: To investigate the changes in bispectral index (BIS) to determine the controllability and safety of intravenous anesthesia with propofol and remifentanil in different-aged children. PATIENTS AND METHODS: Forty cases of ASA levels I or II were divided into four groups (A group, ≤ three months old; B group, three months to two years old; C group, two years to six years old; and D group, six years to 12 years old) with 10 cases in each group. Propofol and remifentanil were used in anesthesia induction and maintenance. Hemodynamic changes, BIS values, and sedation scores during T1, T2, T3, T4, T5, T6, and T7, as well as spontaneous breathing recovery and extubation times, were recorded.
RESULTS: Compared with that at T1, the BIS values at T2, T3, T4, T5, and T6 decreased (p < 0.01). SBP, DBP, and HR also decreased (p < 0.01). Compared with the other groups, the extubation time of A group increased (p < 0.01). At T2, T3, T4, T5, T6, and T7, the BIS values of A group were all less than those of C group (p < 0.01).
CONCLUSIONS: Anesthesia is stable and safe when the same unit doses of propofol and remifentanil are administered to different-aged children. In infants under three months, the BIS values were lower, with prolonged palinesthesia time.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25635976

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  2 in total

1.  Variation of bispectral index in children aged 1-12 years under propofol anesthesia: an observational study.

Authors:  Fang Wang; Jianmin Zhang; Jie Yu; Muyang Tian; Xiaohuan Cui; Anshi Wu
Journal:  BMC Anesthesiol       Date:  2019-08-07       Impact factor: 2.217

2.  Propofol use in newborns and children: is it safe? A systematic review.

Authors:  Eduardo Mekitarian Filho; Mariana Barbosa Riechelmann
Journal:  J Pediatr (Rio J)       Date:  2020-01-08       Impact factor: 2.990

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.